Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | CASR | P41180 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | LTC4S | Q16873 | 2/20 | 0.48 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19286310 | 1.00 | ALDH1A1 (0.52) | ALDH1A1CYP1A2CYP2C9CYP2C19CASR | |
| SCHEMBL12871845 | 0.85 | ALDH1A1 (0.54) | ALDH1A1CYP1A2CYP2C9CYP2C19CASR | |
| SCHEMBL15540540 | 0.85 | ALDH1A1 (0.54) | ALDH1A1CYP1A2CYP2C9CYP2C19CASR | |
| SCHEMBL1252229 | 0.83 | ALDH1A1 (0.52) | ALDH1A1CYP1A2CYP2C9CYP2C19CASR | |
| SCHEMBL1253481 | 0.83 | ALDH1A1 (0.52) | ALDH1A1CYP1A2CYP2C9CYP2C19CASR | |
| SCHEMBL31085545 | 0.83 | ALDH1A1 (0.52) | ALDH1A1CYP1A2CYP2C9CYP2C19CASR | |
| Hydrochloric Acid SCHEMBL607851 | 0.83 | ALDH1A1 (0.52) | ALDH1A1CYP1A2CYP2C9CYP2C19CASR | |
| SCHEMBL178500 | 0.83 | ALDH1A1 (0.52) | ALDH1A1CYP1A2CYP2C9CYP2C19CASR | |
| SCHEMBL25453200 | 0.82 | ALDH1A1 (0.50) | ALDH1A1CYP1A2CYP2C9CYP2C19CASR | |
| SCHEMBL13302605 | 0.82 | ALDH1A1 (0.50) | ALDH1A1CYP1A2CYP2C9CYP2C19CASR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183415-B2 | Methods of synthesizing cinacalcet and salts thereof | AMGEN, INC. (US) | 2012-05-22 | — | — | US | disclosed |
| US-8183415-B2 | Methods of synthesizing cinacalcet and salts thereof | AMGEN, INC. (US) | 2012-05-22 | — | — | US | disclosed |
| US-20110281954-A1 | METHODS OF SYNTHESIZING CINACALCET AND SALTS THEREOF | AMGEN INC. | 2011-11-17 | — | — | US | disclosed |
| US-20110281954-A1 | METHODS OF SYNTHESIZING CINACALCET AND SALTS THEREOF | AMGEN INC. | 2011-11-17 | — | — | US | disclosed |
| US-20090137837-A1 | METHODS OF SYNTHESIZING CINACALCET AND SALTS THEREOF | AMGEN INC. | 2009-05-28 | — | — | US | disclosed |
| US-20090137837-A1 | METHODS OF SYNTHESIZING CINACALCET AND SALTS THEREOF | AMGEN INC. | 2009-05-28 | — | — | US | disclosed |
| US-20090137837-A1 | METHODS OF SYNTHESIZING CINACALCET AND SALTS THEREOF | AMGEN INC. | 2009-05-28 | — | — | US | disclosed |
| WO-2009002427-A2 | METHODS OF SYNTHESIZING CINACALCET AND SALTS THEREOF | AMGEN INC. (US) | 2008-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137837-A1 | METHODS OF SYNTHESIZING CINACALCET AND SALTS THEREOF | ACE, SI, REN | ALDH1A1 1814/4885CYP1A2 2370/4885CYP2C9 350/4885 |
| US-20110281954-A1 | METHODS OF SYNTHESIZING CINACALCET AND SALTS THEREOF | ACE, SI, REN | ALDH1A1 1814/4885CYP1A2 2370/4885CYP2C9 350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.